SCHEMBL1649246

SCHEMBL1649246

COCCn1cc(-c2ccc(OCc3ccc(F)cc3)c(C(=O)OC)c2)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 3/20 0.57
IKBKE Q14164 6/20 0.47
TBK1 Q9UHD2 6/20 0.47
USP30 Q70CQ3 1/20 0.45
LIPC P11150 1/20 0.45
LIPG Q9Y5X9 1/20 0.45
FFAR4 Q5NUL3 1/20 0.45
PRKAB2 O43741 1/20 0.44
ABL1 P00519 1/20 0.44
CSF1R P07333 1/20 0.44
LYN P07948 1/20 0.44
TGFBR1 P36897 1/20 0.44
TGFBR2 P37173 1/20 0.44
PRKAG1 P54619 1/20 0.44
SIK1 P57059 1/20 0.44
PRKAA1 Q13131 1/20 0.44
SIK2 Q9H0K1 1/20 0.44
SIK3 Q9Y2K2 1/20 0.44
KAT5 Q92993 1/20 0.44
JAK2 O60674 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10322212 0.86 LRRK2 (0.53) LRRK2IKBKETBK1LIPCFFAR4
SCHEMBL1648915 0.85 LRRK2 (0.82) LRRK2IKBKETBK1
SCHEMBL23535835 0.80 USP30 (0.64) IKBKETBK1USP30PRKAB2ABL1
SCHEMBL10322660 0.79 LRRK2 (0.67) LRRK2CSF1RHAT1EP300
SCHEMBL1647500 0.77 LRRK2 (0.66) LRRK2FFAR4ALDH1A1LMNA
SCHEMBL1650150 0.77 LRRK2 (0.69) LRRK2HAT1EP300
SCHEMBL6916617 0.77 LRRK2 (0.83) LRRK2
SCHEMBL1646768 0.75 LRRK2 (0.51) LRRK2IKBKETBK1LIPCABL1
SCHEMBL23535709 0.74 USP30 (0.59) IKBKETBK1USP30PRKAB2ABL1
SCHEMBL1648615 0.73 LRRK2 (0.79) LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2483254-B1 NOVEL COMPOUNDS GLAXO GROUP LTD (GB) 2014-08-13 EP disclosed
US-8778939-B2 Compounds GLAXO GROUP LIMITED (GB) 2014-07-15 US disclosed
EP-2483254-A1 NOVEL COMPOUNDS Glaxo Group Limited (GB) 2012-08-08 EP disclosed
US-20120184553-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-07-19 US disclosed
WO-2011038572-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2011-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184553-A1 NOVEL COMPOUNDS LRRK2, PARK7, PINK1 LRRK2 1/4885IKBKE 1290/4885TBK1 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.